Publications

1. Biran N, Jacobus S, Vesole DH, Callander NS, Fonseca R, Williams ME, Abonour R, Katz MS, Rajkumar SV, Greipp PR, Siegel DS. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Blood Cancer J. 2016 Sep 2; 6 (9):e466 Epub 2016 Sept 02
   View PubMed
2. Kapoor P, Paludo J, Vallumsetla N, Greipp PR. Waldenstrom macroglobulinemia: What a hematologist needs to know. Blood Rev. 2015 Sep; 29 (5):301-19 Epub 2015 Mar 24
   View PubMed
3. Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA, Saenger AK, Grogan M, Zeldenrust SR, Hayman SR, Buadi F, Greipp PR, Leung N, Russell SR, Dingli D, Lust JA, Rajkumar SV, Jaffe AS. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart. 2014 Mar; 100 (5):383-8 Epub 2014 Jan 08
   View PubMed
4. Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, Zeldenrust SR, McCurdy A, Greipp PR, Kyle RA, Rajkumar SV, Gertz MA. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013 Dec 20; 31 (36):4529-35 Epub 2013 Nov 18
   View PubMed
5. Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 2013 Jan; 27 (1):220-5 Epub 2012 Aug 20
   View PubMed
6. Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, Greipp PR, Hayman SR, Kumar SK, Lust JA, Russell SJ, Witzig TE, Mikhael J, Leung N, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012 Jul; 87 (7):647-51 Epub 2012 May 02
   View PubMed
7. Wagner LI, Robinson D, Weiss M, Katz M, Greipp P, Fonseca R, Cella D. Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manage. 2012 Jun; 43(6):1094-104. Epub 2012 May 09.
   View PubMed
8. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24; 119 (21):4860-7 Epub 2012 Apr 13
   View PubMed
9. Xie Z, Ghosh CC, Patel R, Iwaki S, Gaskins D, Nelson C, Jones N, Greipp PR, Parikh SM, Druey KM. Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome). Blood. 2012 May 3; 119(18):4321-32. Epub 2012 Mar 12.
   View PubMed
10. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20; 30 (9):989-95 Epub 2012 Feb 13
    View PubMed
11. Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, Kumar SK, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, Kyle RA. Immunoglobulin D amyloidosis: a distinct entity. Blood. 2012 Jan 5; 119 (1):44-8 Epub 2011 Nov 07
    View PubMed
12. Vesole DH, Oken MM, Heckler C, Greipp PR, Katz MS, Jacobus S, Morrow GR. Oral antibiotic prophylaxis of early infection in multiple myeloma: A URCC/ECOG randomized phase III study. Leukemia. 2012; 26(12):2517-20.
    View PubMed
13. Jacobus SJ, Kumar S, Uno H, Van Wier, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol. 2011 Nov; 155(3):340-8. Epub 2011 Sep 09.
    View PubMed
14. Chen CY, Senac JS, Weaver EA, May SM, Jelinek DF, Greipp P, Witzig T, Barry MA. Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res. 2011 Nov 1; 17 (21):6712-22 Epub 2011 Sept 02
    View PubMed
15. Kapoor P, Thenappan T, Singh E, Kumar S, Greipp PR. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med. 2011 Nov; 124(11):1006-15.
    View PubMed
16. D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, Kumar S, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, Dispenzieri A. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011 Oct 27; 118 (17):4663-5 Epub 2011 Aug 31
    View PubMed
17. Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011 Oct 20; 118 (16):4359-62 Epub 2011 Aug 22
    View PubMed
18. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15; 118 (11):2970-5 Epub 2011 June 20
    View PubMed
19. Larsen JT, Chee CE, Lust JA, Greipp PR, Rajkumar SV. Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood. 2011 Sep 8; 118 (10):2702-7 Epub 2011 July 12
    View PubMed
20. Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, Kumar S. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood. 2011 Aug 18; 118 (7):1763-5 Epub 2011 June 14
    View PubMed
21. Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol. 2011 Aug; 86 (8):640-5 Epub 2011 May 31
    View PubMed
22. Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Mikhael JR, Roy V, Kyle RA, Greipp PR, Kumar S, Mandrekar SJ. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011 Apr; 25(4):689-96. Epub 2011 Jan 14.
    View PubMed
23. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Dispenzieri A. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011 Jan; 86 (1):12-8
    View PubMed
24. Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, Witzig TE, Lacy MQ, Zeldenrust SR, Rajkumar SV, Russell SJ, Hayman SR, Buadi F, Kumar SK, Dingli D, Dispenzieri A. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol. 2011 Jan; 90(1):101-6. Epub 2010 Jul 20.
    View PubMed
25. Dispenzieri A, Abraham M, Hayman SR, Buadi F, Kumar S, Reeder CB, Mikhael JR, Zeldenrust S, Rajkumar SV, Short KD, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Fonseca R, Bergsagel PL, Roy V, Stewart K, Lacy M. A phase-2 study of pomalidomide and dexamethasone in previously treated light chain (AL) amyloidosis. Blood. 2010 Nov 19; 116(21):434-5.
    
26. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov; 24 (11):1934-9 Epub 2010 Sept 09
    View PubMed
27. Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol. 2010 Oct; 85 (10):737-40
    View PubMed
28. Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC, Kumar S, Greipp PR. Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. Mayo Clin Proc. 2010 Oct; 85 (10):905-12 Epub 2010 July 15
    View PubMed
29. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85 (9):824-33 Epub 2010 Aug 11
    View PubMed
30. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010 Sep; 85 (9):664-9
    View PubMed
31. Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, Blood E, DeGoey R, Henderson K, Kyle RA, Bradwell AR, Greipp PR, Rajkumar SV, Fonseca R. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia. 2010 Aug; 24 (8):1498-505 Epub 2010 June 03
    View PubMed
32. Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, Greipp PR. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia. 2010 Aug; 24 (8):1406-11 Epub 2010 June 10
    View PubMed
33. Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med. 2010 Jul 20; 153 (2):90-8
    View PubMed
34. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010 Jun; 24 (6):1121-7 Epub 2010 Apr 22
    View PubMed
35. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, Kumar S. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc. 2010 Jun; 85 (6):532-7
    View PubMed
36. Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JD, Annunziata CM, Munshi NC. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010 Apr 8; 115(14):2827-34. Epub 2009 Nov 30.
    View PubMed
37. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010 Feb 18; 115 (7):1343-50 Epub 2009 Dec 11
    View PubMed
38. Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR, Barry MA. Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther. 2010 Feb; 21: (2)179-90.
    View PubMed
39. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan; 11 (1):29-37 Epub 2009 Oct 21
    View PubMed
40. Murata K, Clark RJ, Lockington KS, Tostrud LJ, Greipp PR, Katzmann JA. Sharply increased serum free light-chain concentrations after treatment for multiple myeloma. Clin Chem. 2010 Jan; 56 (1):16-8
    View PubMed
41. Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV. Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol. 2009 Dec; 147 (5):677-80 Epub 2009 Sept 14
    View PubMed
42. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009 Dec; 84 (12):1095-110
    View PubMed
43. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, Kumar S, Reeder CB, Zeldenrust SR, Rajkumar SV, Detweiler-Short K, Lust JA, Witzig TE, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Thompson MA, Fonseca R, Stewart AK, Bergsagel PL, Mikhael JR, Roy V, Kyle R, Lacy MQ. A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients. Blood. 2009 Nov 20; 114(22):1482-3.
    
44. Gay F, Hayman S, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel L, Dingli D, Reeder CB, Lust JA, Russel S, Roj V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle R, Greipp PR, Stewart AK, Rajkumar SV. Superiority of lenalidomide-dexamethasone versus thalidomide-dexamethasone as initial therapy for newly diagnosed multiple myeloma. Blood. 2009 Nov 20; 114(22):1494-5.
    
45. Lacy MQ, Jacobus S, Blood EA, Kay NE, Rajkumar SV, Greipp PR. Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leuk Res. 2009 Nov; 33 (11):1485-9 Epub 2009 Feb 24
    View PubMed
46. Madan S, Greipp PR. The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS). Blood Rev. 2009 Nov; 23(6):257-65. Epub 2009 Aug 20.
    View PubMed
47. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20; 27 (30):5008-14 Epub 2009 Aug 31
    View PubMed
48. Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, Buadi FK, Dingli D, Greipp PR, Kumar SK, Lust JA, Rajkumar SV, Russell SJ, Witzig TE. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant. 2009 Oct; 24(10):3132-7. Epub 2009 Apr 29.
    View PubMed
49. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Jul 16; 114 (3):518-21 Epub 2009 Mar 26
    View PubMed
50. Kyle RA, Jacobus S, Friedenberg WR, Slabber CF, Rajkumar SV, Greipp PR. The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. Cancer. 2009 May 15; 115 (10):2155-64
    View PubMed
51. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop RF, Price-Troska T, Henderson K, Sacco A, Azab F, Greipp P, Gertz M, Hayman S, Rajkumar SV, Carpten J, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009 Apr 15; 69 (8):3579-88 Epub 2009 Apr 07
    View PubMed
52. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009 Mar; 94 (3):380-6 Epub 2009 Feb 11
    View PubMed
53. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1beta-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009 Feb; 84 (2):114-22
    View PubMed
54. Patra CR, Verma R, Kumar S, Greipp PR, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticle for potential application in multiple myeloma. J Biomed Nanotechnol. 2008 Dec; 4(4):499-507.
    
55. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Kumar S, Kyle RA, Fonseca R, Greipp PR, Lust JA, Rajkumar VS, Hayman SR, Buadi F, Russell SJ, Zeldenrust SR, Dispenzieri A. A novel report of cig-FISH and cytogenetics in POEMS syndrome. Am J Hematol. 2008 Nov; 83 (11):840-1
    View PubMed
56. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, Melton LJ 3rd, Kumar S, Greipp PR, Clark RJ, Rajkumar SV. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008 Oct; 22 (10):1933-7 Epub 2008 July 03
    View PubMed
57. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica. 2008 Sep; 93(9):1402-6. Epub 2008 Jul 18.
    View PubMed
58. Kapoor P, Snozek CL, Colby C, Larson DR, Katzmann JA, Rajkumar SV, Greipp PR. Clinical impact of discordance in serum albumin measurements on myeloma international staging system. J Clin Oncol 2008 Aug 20; 26 (24):4051-2
    View PubMed
59. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008 Jun; 73 (11):1282-8 Epub 2008 Apr 02
    View PubMed
60. Wang L, Kumar S, Fridley BL, Kalari KR, Moon I, Pelleymounter LL, Hildebrandt MA, Batzler A, Eckloff BW, Wieben ED, Greipp PR. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res. 2008 Jun 1; 14 (11):3503-13
    View PubMed
61. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, Henderson K, Kyle RA, Oken MM, Bradwell AR, Greipp PR. Appraisal of immunoglobulin free light chain as a marker of response. Blood. 2008 May 15; 111 (10):4908-15 Epub 2008 Mar 25
    View PubMed
62. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008 May; 22 (5):1044-52 Epub 2008 Jan 24
    View PubMed
63. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, Kumar S. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp Hematol. 2008 May; 36 (5):568-76 Epub 2008 Mar 17
    View PubMed
64. Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008 Apr 15; 111(8):4039-47. Epub 2008 Feb 11
    View PubMed
65. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol. 2008 Apr; 141(2):135-48. Epub 2008 Mar 03.
    View PubMed
66. Ahmann GJ, Chng WJ, Henderson KJ, Price-Troska TL, DeGoey RW, Timm MM, Dispenzieri A, Greipp PR, Sable-Hunt A, Bergsagel L, Fonseca R. Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. Cancer Epidemiol Biomarkers Prev. 2008 Mar; 17(3):666-73.
    View PubMed
67. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1; 111 (5):2516-20 Epub 2007 Nov 01
    View PubMed
68. Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D, Morgan G. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med. 2008; 6:26. Epub 2008 Sep 8
    View PubMed
69. Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, Schlossman R, Sidor CF, Anderson KC, Gertz MA. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res. 2007 Oct 15; 13 (20):6162-7
    View PubMed
70. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007 Oct; 82 (10):1179-84
    View PubMed
71. Morice WG, Hanson CA, Kumar S, Frederick LA, Lesnick CE, Greipp PR. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia. 2007 Sep; 21(9):2043-6. Epub 2007 Apr 26.
    View PubMed
72. Bhattacharya R, Patra CR, Earl A, Wang SF, Katarya A, Lu LC, Kizhakkedathu JN, Yaszemski MJ, Greipp PR, Mukhopadhyay D, Mukherjee P. Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells. Nanomed. 2007 Sep; 3(3):224-38.
    
73. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007 Aug; 12 (2):131-44
    View PubMed
74. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, Kumar S. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia. 2007 Jul; 21(7):1549-60. Epub 2007 Apr 26.
    View PubMed
75. Snozek CL, Saenger AK, Greipp PR, Bryant SC, Kyle RA, Rajkumar SV, Katzmann JA. Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myeloma. Clin Chem. 2007 Jun; 53 (6):1099-103 Epub 2007 Apr 26
    View PubMed
76. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007 Apr 1; 67(7):2982-9.
    View PubMed
77. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18.
    View PubMed
78. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007 Mar; 82: (3)323-41.
    View PubMed
79. Bhattacharya R, Patra CR, Verma R, Kumar S, Greipp PR, Mukherjee P. Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells. Advanced Materials. 2007 Feb; 19(5):711-6.
    
80. Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 2007 Feb 1; 109 (3):1228-32 Epub 2006 July 13
    View PubMed
81. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007 Jan 15; 109 (2):465-70 Epub 2006 Sept 28
    View PubMed
82. Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC, Garcia-Sanz R, Moro MJ, Aguilera C, Hernandez J, Xu R, Greipp PR, Dispenzieri A, Jalal SM, Lacy MQ, Gonzalez-Paz N, Gertz MA, San Miguel JF, Fonseca R. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007 Jan; 136(1):80-6.
    View PubMed
83. Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp PR, Litzow MR, Price-Troska T, Henderson KJ, Ahmann GJ, Gertz MA. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006 Nov; 20(11):2034-40. Epub 2006 Oct 05.
    View PubMed
84. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006 Oct 15; 108 (8):2755-63 Epub 2006 June 27
    View PubMed
85. Timm MM, Kimlinger TK, Haug JL, Kline MP, Greipp PR, Rajkumar SV, Kumar SK. Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. Leukemia. 2006 Oct; 20(10):1863-9. Epub 2006 Aug 17.
    View PubMed
86. Schop RF, Van Wier SA, Xu R, Ghobrial I, Ahmann GJ, Greipp PR, Kyle RA, Dispenzieri A, Lacy MQ, Rajkumar SV, Gertz MA, Fonseca R. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet. 2006 Sep; 169 (2):150-3
    View PubMed
87. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006 Aug; 81 (8):1047-53
    View PubMed
88. Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ, Peng KW. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol. 2006 Jun; 34 (6):713-20
    View PubMed
89. Kyle RA, Leong T, Li S, Oken MM, Kay NE, Van Ness B, Greipp PR. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer. 2006 May 1; 106(9):1958-66.
    View PubMed
90. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Jacobus S, Blood E, Oken MM, Henderson K, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006 May; 20(5):807-13.
    View PubMed
91. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Rajkumar SV, Lust JA, Kyle RA, Zeldenrust SR, Hayman SR, Fonseca R. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood. 2006 May 1; 107 (9):3669-75 Epub 2005 Dec 22
    View PubMed
92. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006 Apr 15; 107 (8):3378-83 Epub 2006 Jan 05
    View PubMed
93. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman SR, Rajkumar SV, Greipp PR, Litzow MR, Gastineau DA, Witzig TE, Gertz MA. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood. 2006 Apr 15; 107 (8):3384-8 Epub 2005 Dec 08
    View PubMed
94. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, Kyle RA. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006 Apr; 133 (2):158-64
    View PubMed
95. Chng WJ, Winkler JM, Greipp PR, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Ahmann GJ, Henderson K, Blood E, Oken MM, Hulbert A, Van Wier SA, Santana-Davila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R. Ploidy status rarely changes in myeloma patients at disease progression. Leuk Res. 2006 Mar; 30(3):266-71. Epub 2005 Aug 18.
    View PubMed
96. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20; 24(6):929-36. Epub 2006 Jan 23.
    View PubMed
97. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006 Feb 15; 106(4):830-8.
    View PubMed
98. Xiong Y, Donovan KA, Kline MP, Gornet MK, Moon-Tasson LL, Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Lust JA. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res. 2006 Feb; 26(2):83-95.
    View PubMed
99. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20; 24(3):431-6. Epub 2005 Dec 19.
    View PubMed
100. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR, Rajkumar SV, Kimlinger T, Lust JA, Fonseca R, Allred J, Witzig TE. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma. 2006 Jan; 47 (1):39-42
     View PubMed
101. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15; 106 (13):4050-3 Epub 2005 Aug 23
     View PubMed
102. Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica. 2005 Dec; 90: (12)1650-4.
     View PubMed
103. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, Van Wier SA, Ahmann GJ, Fonseca R. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005 Oct 15; 106 (8):2837-40 Epub 2005 June 23
     View PubMed
104. Greipp P. Treatment paradigms for the newly diagnosed patient with multiple myeloma. Semin Hematol. 2005 Oct; 42 (4 Suppl 4):S16-21
     View PubMed
105. Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, Lust JA, Dispenzieri A, Greipp PR, Kyle RA, Rajkumar SV. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005 Oct 1; 106 (7):2276-9 Epub 2005 June 16
     View PubMed
106. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Oken MM, Blood E, Henderson K, Santana-Davila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005 Sep 15; 106 (6):2156-61 Epub 2005 May 26
     View PubMed
107. Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. Journal of Clinical Oncology. 2005 Aug 20; 23(24):5668-74.
     View PubMed
108. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia. 2005 Aug; 19 (8):1466-70
     View PubMed
109. Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol. 2005 Jul; 33(7):784-95.
     View PubMed
110. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20; 23 (15):3412-20 Epub 2005 Apr 04
     View PubMed
111. Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia. 2005 Jan; 19: (1)118-25.
     View PubMed
112. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA, Eastern Cooperative Oncology Group. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004 Dec 1; 101 (11):2593-8
     View PubMed
113. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004 Oct; 45 (10):2047-55
     View PubMed
114. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15; 22 (18):3751-7
     View PubMed
115. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004 Sep 15; 104 (6):1881-7 Epub 2004 Mar 25
     View PubMed
116. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant. 2004 Sep; 34(6):485-90.
     View PubMed
117. Kumar S, Rajkumar SV, Greipp PR, Witzig TE. Cell proliferation of myeloma plasma cells: Comparison of the blood and marrow compartments. Am J Hematol. 2004 Sep; 77(1):7-11.
     View PubMed
118. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK, Greipp PR, Rajkumar SV. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004 Aug 15; 104(4):1159-65. Epub 2004 May 06.
     View PubMed
119. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004 Aug; 34(3):235-9.
     View PubMed
120. Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, Fonseca R, Kyle RA, Gertz MA. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood. 2004 Jul 1; 104 (1):40-2 Epub 2004 Mar 09
     View PubMed
121. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004 Jul; 79 (7):867-74
     View PubMed
122. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004 Jul; 34(2):161-7.
     View PubMed
123. Gertz MA, Blood E, Vesole DH, Abonour R, Lazarus HM, Greipp PR. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant. 2004 Jul; 34(2):149-54.
     View PubMed
124. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004 May 15; 103 (10):3960-3 Epub 2004 Jan 22
     View PubMed
125. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May 1; 103(9):3271-7. Epub 2004 Jan 15.
     View PubMed
126. Greipp P, Multiple Myeloma Research Foundation. Prognostic indicators for the diagnosis of multiple myeloma. Oncology (Williston Park). 2004 May; 18(5):558-60.
     View PubMed
127. Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia. 2004 Mar; 18(3):624-7.
     View PubMed
128. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004 Mar 1; 103 (5):1641-6 Epub 2003 Nov 06
     View PubMed
129. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004 Feb 15; 64 (4):1546-58
     View PubMed
130. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004 Jan 15; 103 (2):689-94 Epub 2003 Sept 25
     View PubMed
131. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R, Lust JA, Greipp PR, Kyle RA, Gertz MA. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003 Dec; 10 (4):257-61
     View PubMed
132. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Davila R, Gonzalez-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003 Oct 1; 102 (7):2562-7 Epub 2003 June 12
     View PubMed
133. Thompson MA, Witzig TE, Kumar S, Timm MM, Haug J, Fonseca R, Greipp PR, Lust JA, Rajkumar SV. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol. 2003 Oct; 123(2):305-8.
     View PubMed
134. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003 Oct; 17(10):2025-31.
     View PubMed
135. Kumar S, Witzig TE, Greipp PR, Rajkumar SV. Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. Br J Haematol. 2003 Jul; 122 (2):272-4
     View PubMed
136. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003 Jun 1; 101(11):4569-75.
     View PubMed
137. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003 Apr; 17(4):775-9.
     View PubMed
138. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, Greipp PR, Witzig TE, Basu R, Suarez GA, Fonseca R, Lust JA, Gertz MA. POEMS syndrome: definitions and long-term outcome. Blood. 2003 Apr 1; 101 (7):2496-506 Epub 2002 Nov 27
     View PubMed
139. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, Miguel JFS, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):110-5.
     View PubMed
140. Rajkumar SV, Hayman S, Greipp PR. Angiogenesis in Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):262-4.
     View PubMed
141. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003 Mar 1; 101 (5):1715-7 Epub 2002 Oct 17
     View PubMed
142. Greipp PR. Eastern Cooperative Oncology Group E1A00: phase III randomized study of dexamethasone with or without thalidomide in patients with newly diagnosed multiple myeloma. Clin Adv Hematol Oncol. 2003 Mar; 1(3):188-9.
     View PubMed
143. Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Greipp PR, Gertz MA, Rajkumar SV. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood. 2003 Feb 1; 101 (3):827-30 Epub 2002 Sept 05
     View PubMed
144. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, Winkler JM, Kyle RA, Gertz MA, Witzig TE, Dispenzieri A, Lacy MQ, Rajkumar SV, Lust JA, Greipp PR, Fonseca R. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003 Feb; 17 (2):427-36
     View PubMed
145. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc. 2003 Jan; 78(1):34-9.
     View PubMed
146. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003 Jan; 78 (1):21-33
     View PubMed
147. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol. 2002 Dec; 119 (3):665-71
     View PubMed
148. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002 Nov 1; 20: (21)4319-23.
     View PubMed
149. Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, Jalal SM, Qi Y, Kyle RA, Greipp PR, Fonseca R. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002 Oct 15; 100 (8):2996-3001
     View PubMed
150. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002 Aug 15; 100 (4):1417-24
     View PubMed
151. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR, Mayo Clinic Myeloma Amyloid and Dysproteinemia Group. Current therapy for multiple myeloma. Mayo Clin Proc. 2002 Aug; 77(8):813-22.
     View PubMed
152. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002 Jul; 8(7):2210-6.
     View PubMed
153. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Greipp PR. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002 May 15; 99 (10):3735-41
     View PubMed
154. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay NE, Van Ness B, Greipp PR. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res. 2002 Feb 1; 62(3):715-20.
     View PubMed
155. Schop RF, Jalal SM, Van Wier SA, Ahmann GJ, Bailey RJ, Kyle RA, Greipp PR, Rajkumar SV, Gertz MA, Lust JA, Lacy MQ, Dispenzieri A, Witzig TE, Fonseca R. Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet. 2002 Jan 1; 132 (1):55-60
     View PubMed
156. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Therneau TM, Kyle RA, Greipp PR, Gertz MA. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001 Dec; 68 (4):269-75
     View PubMed
157. Hayman SR, Bailey RJ, Jalal SM, Ahmann GJ, Dispenzieri A, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Rajkumar SV, Witzig TE, Lust JA, Fonseca R. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001 Oct 1; 98 (7):2266-8
     View PubMed
158. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001 Oct 1; 98 (7):2002-7
     View PubMed
159. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001 Aug; 15 (8):1274-6
     View PubMed
160. Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Gertz MA. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001 Jul 15; 19: (14)3350-6.
     View PubMed
161. Kay NE, Leong TL, Bone N, Vesole DH, Greipp PR, Van Ness B, Oken MM, Kyle RA. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood. 2001 Jul 1; 98 (1):23-8
     View PubMed
162. Rajkumar SV, Greipp PR. Angiogenesis in multiple myeloma. Br J Haematol. 2001 Jun; 113 (3):565
     View PubMed
163. Fonseca R, Conte G, Greipp PR. Laboratory correlates in multiple myeloma: how useful for prognosis? Blood Rev. 2001 Jun; 15(2):97-102.
     View PubMed
164. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Greipp PR, Dewald GW. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001 Jun; 15 (6):981-6
     View PubMed
165. Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, Offord JR, Plevak MF, Therneau TM, Witzig TE. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood. 2001 Apr 15; 97 (8):2522-3
     View PubMed
166. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Larson D, Therneau TM, Kyle RA, Litzow MR, Greipp PR, Gertz MA. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant. 2000 Nov; 26(9):979-83.
     View PubMed
167. Fonseca R, Rajkumar SV, Ahmann GJ, Jalal SM, Hoyer JD, Gertz MA, Kyle RA, Greipp PR, Dewald GW. Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis. Leuk Lymphoma. 2000 Oct; 39 (3-4):391-5
     View PubMed
168. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000 Sep; 75(9):897-901.
     View PubMed
169. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000 Aug; 6 (8):3111-6
     View PubMed
170. Gertz MA, Lacy MQ, Inwards DJ, Gastineau DA, Tefferi A, Chen MG, Witzig TE, Greipp PR, Litzow MR. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant. 2000 Jul; 26(1):45-50.
     View PubMed
171. Witzig TE, Meyers C, Therneau T, Greipp PR. A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders. Leuk Lymphoma. 2000 Jul; 38 (3-4):345-50
     View PubMed
172. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol. 2000 Jun; 113(6):831-7.
     View PubMed
173. Greipp PR. Smoldering, asymptomatic stage 1, and indolent myeloma. Curr Treat Options Oncol. 2000 Jun; 1 (2):119-26
     View PubMed
174. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol. 2000 Apr; 109(1):24-9.
     View PubMed
175. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Therneau TM. Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000 Mar; 108 (4):737-42
     View PubMed
176. Fonseca R, Greipp PR. Multiple myeloma. Conn's Current Therapy. 2000; 466-9.
     
177. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am. 1999 Dec; 13 (6):1295-314, xi
     View PubMed
178. Fonseca R, Hoyer JD, Aguayo P, Jalal SM, Ahmann GJ, Rajkumar SV, Witzig TE, Lacy MQ, Dispenzieri A, Gertz MA, Kyle RA, Greipp PR. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leuk Lymphoma. 1999 Nov; 35 (5-6):599-605
     View PubMed
179. Oken MM, Leong T, Lenhard RE Jr, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer. 1999 Sep 15; 86(6):957-68.
     View PubMed
180. Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999 Sep; 24(5):497-503.
     View PubMed
181. Greipp PR, Trendle MC, Leong T, Oken MM, Kay NE, Van Ness B, Kyle RA. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma. 1999 Sep; 35 (1-2):83-9
     View PubMed
182. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA, Greipp PR, Gertz MA. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999 Aug; 113 (1):73-7
     View PubMed
183. Ansell SM, Kurtin PJ, Stenson M, Habermann TM, Greipp PR, Therneau TM, Witzig TE. Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index. Leuk Lymphoma. 1999 Aug; 34 (5-6):529-37
     View PubMed
184. Trendle MC, Leong T, Kyle RA, Katzmann JA, Oken MM, Kay NE, Van Ness BG, Greipp PR. Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486. Am J Hematol. 1999 Aug; 61 (4):232-7
     View PubMed
185. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol. 1999 Jul; 16 (2):104-9
     View PubMed
186. Tahirkheli NK, Greipp PR. Treatment of the systemic capillary leak syndrome with terbutaline and theophylline. A case series. Ann Intern Med. 1999 Jun 1; 130 (11):905-9
     View PubMed
187. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 1999 Jun; 23(12):1267-72.
     View PubMed
188. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Am J Hematol. 1999 Jun; 61 (2):115-9
     View PubMed
189. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Beta(2)-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant. 1999 Jun; 23(12):1261-1266.
     View PubMed
190. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Therneau TM, Kyle RA, Litzow MR, Gertz MA, Greipp PR. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999 May; 17: (5)1551-7.
     View PubMed
191. Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 1999 Mar; 13 (3):469-72
     View PubMed
192. Kay N, Leong T, Kyle RA, Greipp P, Van Ness B, Bone N, Oken MM. Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma. 1999 Mar; 33(1-2):127-33.
     View PubMed
193. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999 Feb 1; 93 (3):1062-6
     View PubMed
194. Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineau DA, Greipp PR, Lust JA, Tefferi A, Witzig TE, Kyle RA, Litzow MR. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant. 1999 Feb; 23(3):221-6.
     View PubMed
195. Witzig TE, Timm M, Larson D, Therneau T, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol. 1999 Jan; 104 (1):131-7
     View PubMed
196. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol. 1999 Jan; 17: (1)262-7.
     View PubMed
197. Fonseca R, Ahmann GJ, Jalal SM, Dewald GW, Larson DR, Therneau TM, Gertz MA, Kyle RA, Greipp PR. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 1998 Dec; 103 (3):704-10
     View PubMed
198. Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA. Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93). Am J Clin Oncol. 1998 Dec; 21(6):553-6.
     View PubMed
199. Mongkonsritragoon W, Kyle RA, Shreck RR, Greipp PR. Primary plasmacytoma at the site of exit wounds after electrical injury. Am J Hematol. 1998 May; 58 (1):77-9
     View PubMed
200. Mongkonsritragoon W, Kimlinger T, Ahmann G, Greipp PR. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis? Leuk Lymphoma. 1998 May; 29 (5-6):577-84
     View PubMed
201. Fonseca R, Witzig TE, Gertz MA, Kyle RA, Hoyer JD, Jalal SM, Greipp PR. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol. 1998 May; 101 (2):296-301
     View PubMed
202. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, Oken MM, Kay NE, Van Ness B, Kyle RA. Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998 Apr 1; 91 (7):2501-7
     View PubMed
203. Kay NE, Leong T, Bone N, Kyle RA, Greipp PR, Van Ness B, Oken MM. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br J Haematol. 1998 Mar; 100(3):459-63.
     View PubMed
204. Ahmann GJ, Jalal SM, Juneau AL, Christensen ER, Hanson CA, Dewald GW, Greipp PR. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 1998 Feb; 101 (1):7-11
     View PubMed
205. McElroy EA Jr, Witzig TE, Gertz MA, Greipp PR, Kyle RA. Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis. Br J Haematol. 1998 Feb; 100 (2):326-7
     View PubMed
206. Greipp PR. Novel prognostic factors. Cancer Research, Therapy & Control. 1998; 6(1-4):109-12.
     
207. Greipp PR. Bisphosphonates for myeloma - current approach to treatment. Myeloma Today. 1998 Spring; 2(10).
     
208. Papagelopoulos PJ, Galanis EC, Greipp PR, Sim FH. Prosthetic hip replacement for pathologic or impending pathologic fractures in myeloma. Clin Orthop. 1997 Aug; 341:192-205.
     View PubMed
209. Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, Bone N, Oken MM. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood. 1997 Jul 1; 90(1):340-5.
     View PubMed
210. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24; 336 (17):1202-7
     View PubMed
211. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant. 1997 Feb; 19 (4):337-42
     View PubMed
212. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van Ness B. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996 Oct 1; 88(7):2699-706.
     View PubMed
213. Witzig TE, Gertz MA, Lust JA, Kyle RA, O'Fallon WM, Greipp PR. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood. 1996 Sep 1; 88 (5):1780-7
     View PubMed
214. Blade J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med. 1996 Jul 8; 156 (13):1463-8
     View PubMed
215. Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR, Witzig TE. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood. 1996 Jul 1; 88(1):289-96.
     View PubMed
216. Witzig TE, Kimlinger TK, Ahmann GJ, Katzmann JA, Greipp PR. Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry. 1996 Jun 15; 26 (2):113-20
     View PubMed
217. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996 May; 93 (2):345-51
     View PubMed
218. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia. 1996 May; 10(5):866-76.
     View PubMed
219. Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Gregory SA, Spiegel RJ, Oconnell MJ. Complete remission induction with combined VBCMP chemotherapy and interferon (rIFN(alpha-2B)) in patients with multiple myeloma. Leuk Lymphoma. 1996 Feb; 20(5-6):447-452.
     View PubMed
220. Greipp PR, Witzig T, Witzig T. Biology and treatment of myeloma. Curr Opin Oncol. 1996 Jan; 8 (1):20-7
     View PubMed
221. Bartlett RP, Greipp PR, Tefferi A, Cupps RE, Mullan BP, Trastek VF. Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc. 1995 Dec; 70 (12):1161-4
     View PubMed
222. Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia. 1995 Dec; 9(12):2115-8.
     View PubMed
223. Witzig TE, Gertz MA, Lust JA, Kyle RA, Greipp PR. Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest? Leuk Lymphoma. 1995 Nov; 19 (5-6):417-22
     View PubMed
224. Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, Kyle RA. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med. 1995 Oct 23; 155(19):2069-74.
     View PubMed
225. Witzig TE, Habermann TM, Kurtin PJ, Schroeder G, Stenson MJ, Greipp PR. S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. Cancer. 1995 Sep 15; 76 (6):1059-64
     View PubMed
226. Greipp PR, Lust JA. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Stem Cells. 1995 Aug; 13 Suppl 2:10-21.
     View PubMed
227. Krett NL, Pillay S, Moalli PA, Greipp PR, Rosen ST. A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients. Cancer Res. 1995 Jul 1; 55(13):2727-9.
     View PubMed
228. Mathew P, Ahmann GJ, Witzig TE, Roche PC, Kyle RA, Greipp PR. Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity? Br J Haematol. 1995 Jun; 90 (2):459-61
     View PubMed
229. Witzig TE, Gertz MA, Pineda AA, Kyle RA, Greipp PR. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br J Haematol. 1995 Mar; 89 (3):640-2
     View PubMed
230. Gertz MA, Pineda AA, Chen MG, Letendre L, Greipp PR, Solberg LA Jr, Witzig TE, Garton JP, Inwards DJ, Litzow MR. Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. Am J Med Sci. 1995 Mar; 309 (3):152-61
     View PubMed
231. Witzig TE, Kimlinger TK, Greipp PR. Detection of peripheral blood myeloma cells by three-color flow cytometry. Curr Top Microbiol Immunol. 1995; 194:3-8
     View PubMed
232. Kay NE, Oken MM, Kyle R, Van Ness B, Kalish L, Leong T, Greipp P. Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells. Leukemia & Lymphoma. 1995 Jan; 16(3-4):351-4.
     View PubMed
233. Billadeau D, Greipp P, Ahmann G, Witzig T, Van Ness B. Detection of B-cells clonally related to the tumor population in multiple myeloma and MGUS. Current Topics in Microbiology & Immunology. 1995; 194:9-16.
     View PubMed
234. Westendorf JJ, Ahmann GJ, Lust JA, Tschumper RC, Greipp PR, Katzmann JA, Jelinek DF. Molecular and biological role of CD40 in multiple myeloma. Curr Top Microbiol Immunol. 1995; 194:63-72
     View PubMed
235. Tefferi A, Ho TC, Ahmann GJ, Katzmann JA, Greipp PR. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med. 1994 Oct; 97 (4):374-8
     View PubMed
236. Greipp PR. Prognosis in myeloma. Mayo Clin Proc. 1994 Sep; 69 (9):895-902
     View PubMed
237. Menke DM, Greipp PR, Colon-Otero G, Solberg LA Jr, Cockerill KJ, Hook CC, Witzig TE. Bone marrow aspirate immunofluorescent and bone marrow biopsy immunoperoxidase staining of plasma cells in histologically occult plasma cell proliferative marrow disorders. Arch Pathol Lab Med. 1994 Aug; 118(8):811-4.
     View PubMed
238. Witzig TE, Kyle RA, O'Fallon WM, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol. 1994 Jun; 87 (2):266-72
     View PubMed
239. Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol. 1994 Jan 1; 152 (1):117-28
     View PubMed
240. Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA, Lust JA. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res. 1993 Nov 1; 53(21):5320-7.
     View PubMed
241. Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med. 1993 Sep 1; 178(3):1023-31.
     View PubMed
242. Witzig TE, Dhodapkar MV, Kyle RA, Greipp PR. Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer. 1993 Jul 1; 72 (1):108-13
     View PubMed
243. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993 Jun 15; 81 (12):3382-7
     View PubMed
244. Greipp PR, Lust JA. Role of cytokines in the pathogenesis and treatment of multiple myeloma. Myeloma Today. 1993; 1:4-5.
     
245. Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, Van Ness B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood. 1992 Oct 1; 80(7):1818-24.
     View PubMed
246. Greipp PR. Advances in the diagnosis and management of myeloma. Semin Hematol. 1992 Jul; 29 (3 Suppl 2):24-45
     View PubMed
247. Greipp PR. State of the art management of monoclonal gammopathies. The Practice of Internal Medicine-1992. 1992 May 11-15; 171-4.
     
248. Droder RM, Kyle RA, Greipp PR. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med. 1992 May; 92 (5):523-6
     View PubMed
249. Tefferi A, Greipp PR, Leibson PJ, Thibodeau SN. Demonstration of clonality, by X-linked DNA analysis, in chronic natural killer cell lymphocytosis and successful therapy with oral cyclophosphamide. Leukemia. 1992 May; 6(5):477-80.
     View PubMed
250. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine. 1992 Mar; 4 (2):96-100
     View PubMed
251. Witzig TE, Kyle RA, Greipp PR. Circulating peripheral blood plasma cells in multiple myeloma. Curr Top Microbiol Immunol. 1992; 182:195-9
     View PubMed
252. Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood. 1991 Dec 1; 78(11):3021-9.
     View PubMed
253. Witzig TE, Gonchoroff NJ, Ahmann GA, Katzmann JA, Greipp PR. T cell depletion using anti-CD2 coated magnetic beads simplifies the detection of peripheral blood plasma cells. J Immunol Methods. 1991 Nov 22; 144 (2):253-6
     View PubMed
254. Gertz MA, Greipp PR, Kyle RA. Classification of amyloidosis by the detection of clonal excess of plasma cells in the bone marrow. J Lab Clin Med. 1991 Jul; 118:33-9.
     View PubMed
255. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood. 1991 Jan 15; 77 (2):257-62
     View PubMed
256. Beauregard P, Witzig TE, Kurtin PJ, Greipp PR, Stenson MJ, Katzmann JA, Habermann TM, Wieand HS. Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling index. Hematol Pathol. 1991; 5(4):177-83.
     View PubMed
257. Gertz MA, Kyle RA, Greipp PR, Katzmann JA, O'Fallon WM. Beta 2-microglobulin predicts survival in primary systemic amyloidosis. Am J Med. 1990 Nov; 89 (5):609-14
     View PubMed
258. Witzig TE, Banks PM, Stenson MJ, Griepp PR, Katzmann JA, Habermann TM, Colgan JP, Gonchoroff NJ. Rapid immunotyping of B-cell non-Hodgkin's lymphomas by flow cytometry. A comparison with the standard frozen-section method. Am J Clin Pathol. 1990 Sep; 94 (3):280-6
     View PubMed
259. Adachi M, Tefferi A, Greipp PR, Kipps TJ, Tsujimoto Y. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med. 1990 Feb 1; 171(2):559-64.
     View PubMed
260. Gonchoroff NJ, Ryan JJ, Kimlinger TK, Witzig TE, Greipp PR, Meyer JS, Katzmann JA. Effect of sonication on paraffin-embedded tissue preparation for DNA flow cytometry. Cytometry. 1990; 11(5):642-6.
     View PubMed
261. Greipp PR. Cell kinetics and flow cytometry in multiple myeloma. Clinical Immunology Newsletter. 1990; 10:89-92.
     
262. Greipp PR. Monoclonal gammopathies: new approaches to clinical problems in diagnosis and prognosis. Blood Rev. 1989 Dec; 3 (4):222-36
     View PubMed
263. Gertz MA, Kyle RA, Greipp PR. The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood. 1989 Aug 15; 74 (3):1108-11
     View PubMed
264. Morgan RJ Jr, Gonchoroff NJ, Katzmann JA, Witzig TE, Kyle RA, Greipp PR. Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma. Am J Hematol. 1989 Apr; 30 (4):195-200
     View PubMed
265. Witzig TE, Gonchoroff NJ, Greipp PR, Katzmann JA, Stenson MJ, Habermann TM, Colgan JP, Therneau TM, Banks PM. Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedure. Am J Clin Pathol. 1989 Mar; 91 (3):298-301
     View PubMed
266. Bourne WM, Kyle RA, Brubaker RF, Greipp PR. Incidence of corneal crystals in the monoclonal gammopathies. Am J Ophthalmol. 1989 Feb 15; 107 (2):192-3
     View PubMed
267. Greipp PR, Coleman M, Anderson K, McIntyre OR. Phase II trial of amsacrine in patients with multiple myeloma. Med Pediatr Oncol. 1989; 17 (1):76-8
     View PubMed
268. Greipp PR, Katzmann JA, O'Fallon WM, Kyle RA. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 1988 Jul; 72 (1):219-23
     View PubMed
269. Witzig TE, Gonchoroff NJ, Katzmann JA, Therneau TM, Kyle RA, Greipp PR. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J Clin Oncol. 1988 Jun; 6: (6)1041-6.
     View PubMed
270. Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O'Fallon WM, Kyle RA. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc. 1987 Nov; 62 (11):969-77
     View PubMed
271. Camoriano JK, Greipp PR, Bayer GK, Bowie EJ. Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. N Engl J Med. 1987 Apr 30; 316(18):1133-5.
     View PubMed
272. Gonchoroff NJ, Katzmann JA, Currie RM, Evans EL, Houck DW, Kline BC, Greipp PR, Loken MR. S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatment. J Immunol Methods. 1986 Oct 23; 93(1):97-101.
     View PubMed
273. Benson MD, Dwulet FE, Scheinberg MA, Greipp P. Chemical classification of hereditary amyloidosis in Brazilian families and identification of gene carriers. J Rheumatol. 1986 Oct; 13(5):927-31.
     View PubMed
274. Katzmann JA, Greipp PR, O'Fallon WM, Kyle RA. Serum beta 2-microglobulin. Mayo Clin Proc. 1986 Sep; 61(9):752-3.
     View PubMed
275. Kyle RA, Greipp PR, Gertz MA. Treatment of refractory multiple myeloma and considerations for future therapy. Semin Oncol. 1986 Sep; 13(3):326-33.
     View PubMed
276. Littlefield BA, Hoagland HC, Greipp PR. Elevated glucocorticoid receptor binding in cultured human lymphoblasts following hydroxyurea treatment: lack of effect on steroid responsiveness. Cancer Res. 1986 Aug; 46(8):3945-50.
     View PubMed
277. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986 Jul; 68(1):220-4.
     View PubMed
278. Gonchoroff NJ, Katzmann JA, Garton JP, Ruiz-Arguelles GJ, Eilers CR, Greipp PR, Kyle RA. A monoclonal antibody reactive with a subset of human plasma cells. Br J Haematol. 1986 Apr; 62(4):619-30.
     View PubMed
279. Woloschak GE, Dewald GW, Bahn RS, Kyle RA, Greipp PR, Ash RC. Amplification of RNA and DNA specific for erb B in unbalanced 1;7 chromosomal translocation associated with myelodysplastic syndrome. J Cell Biochem. 1986; 32(1):23-34.
     View PubMed
280. Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec; 79(6):708-16.
     View PubMed
281. Gonchoroff NJ, Greipp PR, Kyle RA, Katzmann JA. A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. Cytometry. 1985 Nov; 6(6):506-12.
     View PubMed
282. Greipp PR, Witzig TE, Gonchoroff NJ. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1). Am J Hematol. 1985 Nov; 20(3):289-92.
     View PubMed
283. Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, Offord KP, Greipp PR, Edwards WD, Tajik AJ. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985 Oct; 6(4):737-43.
     View PubMed
284. Blum DJ, Doyle JA, Greipp PR, McDonald TJ. Gamma heavy-chain disease involving upper airway. Otolaryngol Head Neck Surg. 1985 Oct; 93: (5)677-9.
     View PubMed
285. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985 Aug; 66(2):380-90.
     View PubMed
286. Otteman LA, Greipp PR, Ruiz-Arguelles GJ, Banks PM, Li CY, Katzmann JA. Infectious mononucleosis mimicking a B cell immunoblastic lymphoma associated with an abnormality in regulatory T cells. Am J Med. 1985 May; 78(5):885-90.
     View PubMed
287. Hall S, McCormick JL Jr, Greipp PR, Michet CJ Jr, McKenna CH. Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. Ann Intern Med. 1985 Mar; 102(3):325-8.
     View PubMed
288. Witzig TE, Greipp PR, Gonchoroff N, Habermann TM, Katzmann JA, Kyle RA. A new immunofluorescence method using a monoclonal antibody (BU-1) for rapid plasma cell labeling indices. Proc Annu Meet Am Soc Clin Oncol. 1985 Mar; 4:10.
     
289. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985 Feb; 65(2):305-10.
     View PubMed
290. VanHale HM, Rogers RS III, Zone JJ, Greipp PR. Pyostomatitis vegetans. A reactive mucosal marker for inflammatory disease of the gut. Arch Dermatol. 1985 Jan; 121(1):94-8.
     View PubMed
291. Greipp PR. Amyloidosis (AL). An approach to early diagnosis. Arch Intern Med. 1984 Nov; 144(11):2145-6.
     View PubMed
292. Cueto-Garcia L, Tajik AJ, Kyle RA, Edwards WD, Greipp PR, Callahan JA, Shub C, Seward JB. Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc. 1984 Sep; 59(9):589-97.
     View PubMed
293. Ruiz-Arguelles GJ, Katzmann JA, Greipp PR, Gonchoroff NJ, Garton JP, Kyle RA. Multiple myeloma: circulating lymphocytes that express plasma cell antigens. Blood. 1984 Aug; 64(2):352-6.
     View PubMed
294. Ruiz-Arguelles GJ, Katzmann JA, Greipp PR, Marin-Lopez A, Gonzalez-Llaven J, Cano-Castellanos R. Lymphocyte subsets in patients with aplastic anemia. Am J Hematol. 1984 Apr; 16(3):267-75.
     View PubMed
295. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983 Oct; 58(10):665-83.
     View PubMed
296. Powell FC, Greipp PR, Su WP. Discoid lupus erythematosus and monoclonal gammopathy. Br J Dermatol. 1983 Sep; 109(3):355-60.
     View PubMed
297. Ackerman SJ, Kephart GM, Habermann TM, Greipp PR, Gleich GJ. Localization of eosinophil granule major basic protein in human basophils. J Exp Med. 1983 Sep 1; 158(3):946-61.
     View PubMed
298. Greipp PR, Kyle RA. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood. 1983 Jul; 62(1):166-71.
     View PubMed
299. Gertz MA, Kyle RA, Greipp PR. Hyposplenism in primary systemic amyloidosis. Ann Intern Med. 1983 Apr; 98(4):475-7.
     View PubMed
300. Kyle RA, Greipp PR. Multiple myeloma. Houses and spouses. Cancer. 1983 Feb 15; 51(4):735-9.
     View PubMed
301. Kyle RA, Greipp PR. 'Idiopathic' Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med. 1982 Mar 11; 306:564-567.
     View PubMed
302. Leiferman KM, O'Duffy JD, Perry HO, Greipp PR, Giuliani ER, Gleich GJ. Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome. JAMA. 1982 Feb 19; 247(7):1018-20.
     View PubMed
303. Greipp PR, Kyle RA, Bowie EJ. Factor-X deficiency in amyloidosis: a critical review. Am J Hematol. 1981 Dec; 11(4):443-50.
     View PubMed
304. Kyle RA, Greipp PR, Banks PM. The diverse picture of gamma heavy-chain disease. Report of seven cases and review of literature. Mayo Clin Proc. 1981 Jul; 56(7):439-51.
     View PubMed
305. Greipp PR, Kyle RA. Clinical brief. Smoldering multiple myeloma. Mayo Clin Proc. 1981 Feb; 56:133-134.
     
306. Kyle RA, Greipp PR. Multiple myeloma and the monoclonal gammopathies. Curr Hematol. 1981; 1:470-522.
     
307. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980 Jun 12; 302(24):1347-9.
     View PubMed
308. Greipp PR, Kyle RA, Bowie EJ. Factor X deficiency in primary amyloidosis: resolution after splenectomy. N Engl J Med. 1979 Nov 8; 301(19):1050-1.
     View PubMed
309. Kyle RA, Greipp PR. Series on clinical testing: 3. The laboratory investigation of monoclonal gammopathies. Mayo Clin Proc. 1978 Nov; 53:719-739.
     View PubMed
310. Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978 Oct; 52(4):818-27.
     View PubMed
311. Thaell JF, Greipp PR, Stubbs SE, Siegal GP. Idiopathic pulmonary hemosiderosis: two cases in a family. Mayo Clin Proc. 1978 Feb; 53(2):113-8.
     View PubMed
312. Geraci JE, Greipp PR, Wilkowske CJ, Wilson WR, Washington JA 2nd. Cardiobacterium hominis endocarditis. Four cases with clinical and laboratory observations. Mayo Clin Proc. 1978 Jan; 53(1):49-53.
     View PubMed
313. Greipp PR, Gralnick HR. Platelet to leukocyte adherence phenomena associated with thrombocytopenia. Blood. 1976 Mar; 47(3):513-21.
     View PubMed
314. Greipp PR, Gau GT, Dockerty MB, Westbrook P, Pluth JR. Thymic cyst presenting as an acute mediastinal mass. Chest. 1973 Jul; 64(1):125-8.
     View PubMed
315. Rogentine G, Rosenberg EB, Merritt CB, Yankee RA, Graw RG, Greipp PR, Whang-Peng J, Fahey JL. Antilymphocyte globulin as the sole immunosuppressant for bone marrow transplantation in aplastic anemia. Transplantation. 1973 May; 15:514-517.
     View PubMed
316. Golde DW, Greipp PR, McGinniss MH. Spectrum of albumin auto-agglutinins. Transfusion (Paris). 1973 Jan-Feb; 13: (1)1-5.
     View PubMed
317. Greipp PR, Brown JA, Gralnick HR. Defibrination in acute pancreatitis. Ann Intern Med. 1972 Jan; 76(1):73-6.
     View PubMed
318. Gralnick HR, Greipp P. Thrombosis with epsilon aminocaproic acid therapy. Am J Clin Pathol. 1971 Aug; 56(2):151-4.
     View PubMed
319. Golde DW, Greipp PR, Senzenbacker L, Gralnick HR. Hematologic abnormalities in fibrogenesis imperfecta ossium. J Bone Joint Surg. 1971 Mar; 53:365-370.
     View PubMed
320. Rogentine G, Rosenberg EB, Merritt CB, Rosenberg SA, Yankee RA, Graw RG, Greipp PR, Whang-Peng J, Fahey JL. Allogeneic bone marrow transplantation in aplastic anemia: a case report. Exp Hematol. 1971; 21:217.